Most cases in those series had, however, defects that are expected to have NROA levels comparable to those of XL-CGD (p22phox and p67phox); i.e., 68.1% in Rawat et al., (genetic defect identified in 59.7%) [9], 98% in Mortaz et al., (genetic defect identified in 88%) [10], and 80% in Koker et al. (genetic defect identified in 94%) [8]. This evidence concerns the gene CYBA and chronic granulomatous disease.